Yue Ma

发表

Evaluation of the Diagnostic Value of the Ultrasound ADNEX Model for Benign and Malignant Ovarian Tumors

X. Peng, Yue Ma, Lingling Wang, 2021, International journal of general medicine.

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

Zicheng Zhang, Yue Ma, Guangyu Wang, 2022, Journal of gastric cancer.

Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment

W. Cheng, Yue Ma, Lingling Wang, 2020, Science and technology of advanced materials.

Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.

Ying Cheng, Jianming Xu, L. Shen, 2021 .

Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis

Qing Yang, Yanqiao Zhang, Yuxin Zhou, 2022, Frontiers in Oncology.

Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.

G. Wang, Yanqiao Zhang, Q. Fan, 2022, European journal of cancer.

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection

Jie Sun, Zicheng Zhang, Yue Ma, 2021, Frontiers in Oncology.

Ubiquitin specific peptidase 5 enhances STAT3 signaling and promotes migration and invasion in Pancreatic Cancer

Yanqiao Zhang, D. Su, Yue Ma, 2020, Journal of Cancer.

China special issue on gastrointestinal tumors‐Regulatory‐immunoscore—A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer

Yanqiao Zhang, D. Su, Yue Ma, 2023, International journal of cancer.

A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.

Yanqiao Zhang, Yue Ma, B. Xing, 2022, Journal of Clinical Oncology.

Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Yanqiao Zhang, Yue Ma, Shiwei Guo, 2021 .

Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.

Jian Li, Yue Ma, Z. Cai, 2023, European Journal of Cancer.

Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD‐mediated pyroptosis in colorectal cancer

Yue Ma, Yuanyu Liao, Lin Fang, 2024, Clinical and translational medicine.

Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study

Yue Ma, Yuanyu Liao, Lin Fang, 2024, Cancer immunology, immunotherapy : CII.

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.

S. Fan, D. Ji, Yue Ma, 2024, European journal of cancer.